Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05329961 · ClinicalTrials.gov registry record · Early Phase 1
Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old
A Early Phase 1 study of Human Papilloma Virus, sponsored by Boston Medical Center.
- Active
- Registry status
- Early Phase 1
- Development phase
- 155
- Enrollment target
- 1
- Study location
NCT05329961 is a Early Phase 1 study of Human Papilloma Virus that is active but no longer recruiting, run by Boston Medical Center. The registered enrollment target is 155 participants, below the 618-participant average among 26 other Human Papilloma Virus trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05329961, a Early Phase 1 study of Human Papilloma Virus, is active but no longer recruiting, sponsored by Boston Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 155 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is an open-label nonrandomized exploratory proof of concept and descriptive 4-year immunogenicity study to assess immunogenicity after administration of a 2-dose regimen of 9-valent human papillomavirus vaccine (9vHPV) vaccine separated by 12 months (months 0, 12).
Conditions Studied
Interventions
- DRUG Gardasil9
Study Locations (1)
Massachusetts
- Boston Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2022-09-26 |
| Est. Completion | 2028-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05329961
The ClinicalTrials.gov registry entry for NCT05329961 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 618-participant average among 26 other Human Papilloma Virus trials with a reported enrollment target (75% lower). The listed sponsor is Boston Medical Center, which has 253 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Human Papilloma Virus appearing as the primary indexed condition, and to 1 intervention - of which Gardasil9 is the first listed.
NCT05329961 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05329961 about?
NCT05329961 is a clinical study titled "Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old". This study is an open-label nonrandomized exploratory proof of concept and descriptive 4-year immunogenicity study to assess immunogenicity after administration of a 2-dose regimen of 9-valent human papillomavirus vaccine (9vHPV) vaccine separated by 12 months (months 0, 12).
What is the current status of trial NCT05329961?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 155 participants. The study started on 2022-09-26. Estimated completion is 2028-12.
What conditions does trial NCT05329961 study?
This clinical trial studies the following conditions: Human Papilloma Virus.
What interventions are being tested in trial NCT05329961?
The interventions under investigation include: Gardasil9 (DRUG).
Who is sponsoring clinical trial NCT05329961?
This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05329961 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Papilloma Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Merck IIT: RRP Pembro and Lenvatinib
RECRUITING · Early Phase 1
-
Educate and Improve Underserved Populations' Uptake and Completion of the HPV Vaccine
RECRUITING · NA
-
Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
RECRUITING · Phase 2
-
PopSci CHW4CervixHealth
RECRUITING · NA
-
Multidimensional and Multimodal Profiling of Oropharyngeal Carcinoma
RECRUITING
-
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.